Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	32.93B
Revenue (ttm)	1.24B
Net Income (ttm)	716.42M
Shares Out	616.79M
EPS (ttm)	1.16
PE Ratio	46.03
Forward PE	107.50
Dividend	0.12 (0.23%)
Ex-Dividend Date	Jun 13, 2025

Volume	3,862,564
Average Volume	10,710,446
Open	53.53
Previous Close	53.53
Day's Range	53.20 - 54.49
52-Week Range	15.22 - 68.68
Beta	0.72
RSI	52.72
Earnings Date	Aug 22, 2025

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. These products are also used in conjunction w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.